SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-014873
Filing Date
2023-08-14
Accepted
2023-08-14 16:34:28
Documents
80
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nrxp-20230630x10q.htm   iXBRL 10-Q 1362911
2 EX-10.1 nrxp-20230630xex10d1.htm EX-10.1 28777
3 EX-31.1 nrxp-20230630xex31d1.htm EX-31.1 15356
4 EX-31.2 nrxp-20230630xex31d2.htm EX-31.2 15420
5 EX-32.1 nrxp-20230630xex32d1.htm EX-32.1 7087
6 EX-32.2 nrxp-20230630xex32d2.htm EX-32.2 6409
  Complete submission text file 0001558370-23-014873.txt   6647341

Data Files

Seq Description Document Type Size
7 EX-101.SCH nrxp-20230630.xsd EX-101.SCH 60256
8 EX-101.CAL nrxp-20230630_cal.xml EX-101.CAL 35466
9 EX-101.DEF nrxp-20230630_def.xml EX-101.DEF 262789
10 EX-101.LAB nrxp-20230630_lab.xml EX-101.LAB 388078
11 EX-101.PRE nrxp-20230630_pre.xml EX-101.PRE 413491
74 EXTRACTED XBRL INSTANCE DOCUMENT nrxp-20230630x10q_htm.xml XML 1039827
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38302 | Film No.: 231171163
SIC: 2834 Pharmaceutical Preparations